What neuropsychiatric side effects can occur with high-dose glucocorticoid therapy and how should they be managed?

Neuropsychiatric Manifestations of Steroid Medication

High-dose glucocorticoid therapy causes neuropsychiatric side effects in 5-20% of patients, with severe manifestations (psychosis, mania, depression, suicidal behavior) occurring at rates of 15.7-22.2 per 100 person-years, and these effects require immediate dose reduction combined with atypical antipsychotics like olanzapine for acute management 1, 2.

Clinical Spectrum and Incidence

The neuropsychiatric effects range across a broad spectrum:

• Mild manifestations: Mood lability, insomnia, anxiety, mild euphoria (most common)
• Moderate manifestations: Depression, hypomania, cognitive impairment
• Severe manifestations: Acute psychosis, mania, severe depression, delirium, suicidal ideation

The incidence varies dramatically by dose. Risk increases sharply once prednisone exceeds 40 mg/day 3, 4. Most patients experience at least some distressing mood, cognitive, or behavioral changes during treatment, though many are subclinical 2.

Notably, one prospective study found that high-dose intravenous corticosteroids for neurological conditions caused only transient mild euphoria that resolved within one month, suggesting the route and indication may influence risk 5. However, this contradicts larger population-based data showing substantial psychiatric risks 6.

Key Risk Factors to Identify

Before initiating medium-to-high dose steroids, assess these specific risk factors:

• Dose-related: >40 mg/day prednisone (strongest predictor), cumulative dose, rapid administration 3, 4
• Patient factors: Prior psychiatric history (especially prior steroid-induced psychosis), female sex, older age 1, 2
• Biological markers: Damaged blood-brain barrier, hypoalbuminemia 3

Critical caveat: Patients with prior steroid-induced psychosis or mania have high recurrence risk with subsequent courses and should receive prophylaxis 3, 7.

Pathophysiology

The mechanisms involve HPA axis dysregulation, neurotransmitter alterations (particularly dopamine and serotonin), neuroinflammation, and structural changes in the hippocampus, amygdala, and prefrontal cortex 1. Understanding this helps explain why symptoms can persist even after discontinuation.

Management Algorithm

Prevention Strategy

For all patients starting medium-to-high dose steroids:

1. Warn patients and caregivers about potential neuropsychiatric symptoms before initiating therapy 3
2. Consider prophylaxis for high-risk patients (prior steroid psychosis, doses >40 mg/day):
   • Lithium or olanzapine are the best-supported prophylactic agents 3
   • Limited trial data support this, but clinical experience suggests meaningful reduction in recurrence

Acute Management When Symptoms Develop

Step 1: Immediate dose reduction if clinically feasible (this alone may be sufficient for mild symptoms) 4

Step 2: If dose reduction insufficient or not possible:

• First-line pharmacological treatment: Atypical antipsychotics, particularly olanzapine 3, 4
• For depressive symptoms: Consider antidepressants
• For manic symptoms: Mood stabilizers or antipsychotics
• Involve liaison psychiatry promptly 3

Step 3: Monitor closely for:

• Suicidal ideation (risk may be increased) 2, 6
• Concurrent metabolic disturbances (hyponatremia can complicate the picture and cause seizures) 7
• Distinguish medication effects from underlying disease or alternative pathology 7

Timeline Considerations

• Anxiety and bipolar symptoms appear particularly elevated in the first weeks of treatment 6
• Most symptoms are reversible, but some cognitive and personality changes may persist long-term 2
• Absolute risk is higher in patients with pre-existing psychiatric disorders 6

Common Pitfalls to Avoid

1. Failing to distinguish steroid-induced symptoms from primary psychiatric disorders or underlying disease activity - this requires multidisciplinary assessment 7
2. Not warning patients preemptively - informed patients can recognize early symptoms
3. Overlooking concurrent medical complications (electrolyte disturbances, cerebrovascular events) that can mimic or complicate psychiatric presentations 7
4. Assuming all patients tolerate steroids similarly - individual vulnerability varies greatly based on the risk factors above

Monitoring Protocol

While the EULAR guideline 8 focuses primarily on physical complications (osteoporosis, cardiovascular disease, diabetes), psychiatric monitoring should be integrated into routine care for patients on medium-to-high dose glucocorticoids, particularly during the first weeks and when doses exceed 40 mg/day prednisone equivalent.

The evidence strongly supports that neuropsychiatric complications are common, clinically significant, and require proactive management rather than reactive treatment 1, 2, 6.